Factory Mutual Insurance Co. purchased a new position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 9,631 shares of the medical research company's stock, valued at approximately $2,589,000.
Other institutional investors and hedge funds have also modified their holdings of the company. BlackRock Inc. purchased a new stake in IQVIA in the 2nd quarter worth approximately $2,811,292,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in IQVIA by 9.0% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,634,264 shares of the medical research company's stock worth $315,772,000 after purchasing an additional 134,997 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in IQVIA by 4.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,657,696 shares of the medical research company's stock worth $282,657,000 after purchasing an additional 66,643 shares during the period. Canada Pension Plan Investment Board bought a new position in IQVIA in the 2nd quarter worth approximately $240,911,000. Finally, Bank of America Corp DE purchased a new stake in IQVIA during the 2nd quarter valued at approximately $235,551,000. Hedge funds and other institutional investors own 89.62% of the company's stock.
Insiders Place Their Bets
In related news, insider James G. Berkshire sold 2,668 shares of the firm's stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the sale, the insider directly owned 10,890 shares in the company, valued at $2,845,883.70. This trade represents a 19.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.70% of the company's stock.
Wall Street Analyst Weigh In
A number of analysts have issued reports on IQV shares. Jefferies Financial Group lifted their price target on shares of IQVIA from $220.00 to $290.00 and gave the company a "buy" rating in a report on Wednesday, July 29th. Mizuho increased their price objective on shares of IQVIA from $275.00 to $300.00 and gave the company an "outperform" rating in a report on Wednesday, October 7th. HSBC raised their price objective on IQVIA from $280.00 to $300.00 and gave the company a "buy" rating in a research report on Tuesday, September 1st. Leerink Partners boosted their target price on IQVIA from $280.00 to $310.00 and gave the stock an "outperform" rating in a research report on Thursday, October 8th. Finally, Evercore boosted their target price on IQVIA from $275.00 to $290.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 6th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, IQVIA presently has a consensus rating of "Moderate Buy" and a consensus target price of $294.21.
View Our Latest Research Report on IQVIA
IQVIA Trading Up 0.5%
Shares of IQV stock opened at $263.93 on Thursday. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $284.50. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.83 and a quick ratio of 0.83. The stock's 50 day simple moving average is $266.30 and its two-hundred day simple moving average is $210.70. The company has a market cap of $43.50 billion, a PE ratio of 22.68, a price-to-earnings-growth ratio of 2.33 and a beta of 1.16.
IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, October 27th. The medical research company reported $3.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.26 by $0.08. The business had revenue of $4.43 billion during the quarter, compared to analyst estimates of $4.37 billion. IQVIA had a return on equity of 30.02% and a net margin of 8.05%. The company's revenue for the quarter was up 8.0% on a year-over-year basis. During the same period last year, the company earned $3.00 EPS. Research analysts predict that IQVIA Holdings Inc. will post 11.53 earnings per share for the current year.
IQVIA Profile
(
Free Report)
IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.
Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.
Read More
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.